1 / 2

Advancements in Laboratory Monitoring of HIV Infection: Testing Frequencies and Virological Failure

This session focuses on key aspects of laboratory monitoring for HIV infection, including ideal frequencies for HIV RNA and CD4 testing, the criteria for defining virological failure based on HIV-1 RNA levels, and the validation requirements for dried blood spots (DBS) used in RNA/DNA testing. Additionally, it discusses the need for improved dual diagnostic tests for HIV-1 and HIV-2. Leading experts Howard Gale, Charlotte Charpentier, Kenneth Ouma, and Dana Raugi will share their insights and findings that could enhance patient care.

heather-cox
Download Presentation

Advancements in Laboratory Monitoring of HIV Infection: Testing Frequencies and Virological Failure

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Questions • LABORATORY MONITORING OF HIV INFECTION: • What is the ideal testing frequency for HIV RNA and CD4 monitoring? • VIRAL SUPPRESSION: • What level of HIV-1 RNA defines “virological” failure? • DRIED BLOOD SPOTS: • Simple/rapid specimen collection and testing – what is required to validate DBS for HIV RNA/DNA? • DUAL HIV-1/-2 INFECTION: • Do we need better dual diagnostic tests for HIV-1/-2? SESSION WEPDB01: Laboratory Monitoring of HIV Infection

  2. Participants • POSTER PRESENTORS • WEPDB0101: Howard Gale, MD, MT (ASCP) • VA Medical Center, Washington, DC • WEPDB0102: Charlotte Charpentier, PharmD, PhD • Laboratoire de Virologie; HôpitalBichat-Claude Bernard; Paris, France • WEPDB0103: Kenneth Ouma, PhD • KEMRI-CDC, Kisumu, Kenya • WEPDB0104: Dana Raugi, MPH • University of Washington, Seattle, WA SESSION WEPDB01: Laboratory Monitoring of HIV Infection

More Related